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Background and purpose of the study: Diabetes mellitus has been recognized as a major risk factor for
osteoporosis in which bone turnover is affected by different mechanisms. As the morbidity, mortality and financial
cost related to osteoporosis are expected to rise in Iran in coming years, and considering the efficacy of AngiparsW
for improvement of different ulcers which made it a new herbal drug in diabetic foot ulcer, there is a need to
evaluate the effect of this new drug on different organs including bone resorption and bone formation markers.
Methods: In this randomized, double- blind clinical trial, 61 diabetic patients were included. The subjects were
randomly divided into intervention and control groups. Subjects of intervention group received 100 mg of
AngiparsW twice a day. Laboratory tests including bone resorption and bone formation markers were performed at
baseline and after 3 months.
Result: 31 patients in study group and 30 patients in control group finished the study. The mean age of the study
population and the mean disease duration was respectively 51.8 ± 6.2 and 7.5 ± 4.7 years with no significant
differences between intervention and control patients. No statistically significant differences between patients and
controls were observed in pyridinoline, osteocalcin, urine calcium, bone alkaline phosphatase and tumor necrosis
factor (TNF-α). Only urine creatinine level significantly changed between two groups after 3 month of treatment (p-
value: 0.029)
Conclusion: In conclusion, the findings of this study indicate that Semelil (AngiparsW) had no beneficial or harmful
effects on bone. It might be other effects of this new component on bone turnover process which need more
studies and more time to be discovered.
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Diabetes mellitus affects skeletal system and bone metabol-
ism through multiple pathways and it has been recognized
as a major risk factor for osteoporosis [1]. Besides, osteo-
porosis is the most prevalent metabolic bone disease,
which dramatically decreases the quality of life and in-
crease financial burden on diabetic patients [2,3].
The relationship between diabetes and osteoporosis
has been the main subject of many researches. Several
mechanisms have been proposed for diabetes-related
osteoporosis. Clinical trials uniformly support the fact* Correspondence: sh_hasani@sina.tums.ac.ir
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distribution, and reproduction in any mediumthat new bone formation and bone quality, are altered in
both types of diabetes. Bone quality changes may be
affected by micro vascular events common in diabetes
[4,5]. Poor glycemic control can induce hypercalciuria
which has been considered a potential risk factor for
osteoporosis in patients with type 2 diabetes [6,7]. Be-
sides, vitamin D deficiency is common in patients with
type 2 diabetes. In the study by Dobnig et al., mean
serum parathyroid hormone (PTH) and osteocalcin
levels were significantly lower in treated type 2 diabetic
patients; therefore, bone formation appears to be
decreased in diabetes [8]. It is shown that bone metabol-
ism and glucose metabolism are associated with each
other through the action of osteocalcin [9]. Also, anCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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ate bone turnover and bone loss in diabetic patients [4].
On the other hand, diabetes mellitus is associated with
oxidative reactions. Many studies showed that increase
in free oxygen radicals could induce tissue damage and
abnormalities in anti-oxidant defenses in diabetes. Oxi-
dative stress can impair the balance between proteolytic
enzymes and their inhibitors that may cause or worsen
osteoporosis in diabetic patients [10]. In vitro studies
have shown that oxidative stress inhibits osteoblastic dif-
ferentiation and induces osteoblast insults and apoptosis.
Thus, oxidative stress may be related to the pathogenesis
of diabetic bone disorders [11-13].
Melilotus officinalis (yellow sweet clover) is a species of a
plant in the family of Feabaceae, native to Eurasia and
introduced in North America, Africa and Australia. Melilo-
tus officinalis contains coumarin, flavonoides (kampeferol,
quercetin glycosides), triterpene saponins and volatile oil.
Melilotus officinalis has antiphlogistic and antiedematous
effects, which explain its use for inflammatory and congest-
ive edema. It increases venous reflux and improves lymph-
atic kinetics [14]. Recent studies have reported a potential
usefulness of administration of Melilotus officinalis extract
for microcirculation improvement and anti-inflammation
effects. Current studies showed that Melilotus officinalis
(AngiparsW) can improve diabetic foot ulcers [15,16]. This
product also decreased nitric oxide (NO) synthesis [17]
which has important effects on bone cell function and plays
an important role in cytokine and inflammation induced
bone loss [18]. Also it has been shown that coumarin and
vitamin-K supplementations increase the serum markers
for bone formation (including osteocalcin and bone alkaline
phosphatase) and may reduce urinary calcium and hydro-
xyproline excretion (well-known markers for bone resorp-
tion). These supplements are two main components of M.
Officinalis extracts [19]. As the morbidity, mortality and fi-
nancial cost related to osteoporosis are expected to rise in
Iran in coming years, and considering the efficacy of Angi-
parsW for improvement of different ulcers which made it a
new herbal drug in diabetic foot ulcer, there is a need to
evaluate the effect of this new drug on different organs in-
cluding bone. Since there is a need for alternative and com-
plementary pharmacotherapy which has better results and
less complications comparing to previous methods and
considering the mechanisms involved in diabetes-induced
osteoporosis [2,20,21], we decided to conduct a randomized
clinical trial to examine the effect of Melilotus officinalis ex-
tract on bone formation and resorption markers in diabetic
patients with osteoporosis.
Materials and methods
A double blind randomized clinical trial was conducted on
diabetic patients referred to the Shariati hospital diabetes
clinic of the Tehran University of Medical Sciences(TUMS). These patients had previously confirmed diabetes
type 2, according to the ADA (American Diabetes Associ-
ation) criteria. The Participants were enrolled to the study
based on the following inclusion and exclusion criteria.
Sixty one diabetic patients, between 40–60 years old,
under treatment with life style modification and/or oral
hypoglycemic agents and no recent inflammatory and
infectious process (at least for the past 4–6 weeks and dur-
ing the study) were included. Patients with chronic disease
such as chronic renal failure (serum creatinine > 270 μmol/
L), chronic liver failure and decompensate heart failure
were excluded. Other exclusion criteria include: coronary
artery bypass graft (CABG), respiratory infectious disease,
proliferative retinopathy, pregnant or lactating females,
childbearing- aged women without safe contraception
methods, diabetic foot ulceration or gangrene, smoking, al-
cohol abuse, hemoglobin a1c (HgA1C) > 9%, any type of
known drug hypersensitivity, malignancy in breast, liver
and genital system, vascular disease, fracture history during
the past 3 years and use of multivitamin supplements and
other traditional drugs in the previous 4–6 weeks, the use
of medications that affect bone metabolism, such as corti-
costeroids, gonadotropin releasing hormone (GnRH) analo-
gous drugs, anticonvulsant, heparin, aluminum-containing
antacids, thyroid hormone, thiazides and supplements con-
taining calcium and other minerals. All patients participat-
ing in this study were under a same lifestyle and were
matched for the drug they used; and also all the patients
received just oral agents (metformin/glybenclamide).
Patients’ inclusion was completely informative and volun-
tary. After inclusion of each patient, complete explanation
was given about the goal of study, probable side effects of
the drug and patients’ rights during the research process.
Then, written informed consent according to institutional
guidelines was obtained before treatment. The study proto-
col was approved by the Medical Ethics Committee of
Medical Sciences/TUMS (code number: 0011).
In this study, sample randomization was based on “Per-
muted Balanced Block” method by an epidemiologist.
Patients were randomly assigned into 2 groups: interven-
tion (n = 31) and control (n = 30). Semelil (AngiparsW) was
prepared by Pars Roos drug company (Tehran, Iran). In the
intervention group, patients received 100 mg of AngiparsW
capsules twice a day. In the control group, participants
received placebo (a non absorbable polymer) with the same
dose. All participants were given a similar lifestyle program.
The patients were followed for a period of three months.
For the primary assessment, a complete set of evalua-
tions was performed which included:
1. A complete past medical history of the trial patients
and an extensive physical examination were done by
a trained physician, a dietary questionnaire
completed at the beginning and the end of the study.
Table 1 Baseline characteristics of subjects in mean ± SD
Variable Group A Group B P-value
Age (yr) 51.87 ± 6.21 51.43 ± 5.37 0.654
BMI (kg/m2) 28.22 ± 3.97 29.98 ± 5.32 0.269
Lumbar T-score −0.36 ± 1.04 −0.25 ± 1.39 0.731
Femoral T-score 0.27 ± 0.97 0.21 ± 1.09 0.833
Fasting blood sugar 166.51 ± 51.97 180.80 ± 74.99 0.148
Duration of diabetes 6 (8) 8.5 (6.5) 0.154
Sex (female) 25 (80.6%) 23 (76.7%) 0.762
Group A: Diabetic patients on drug.
Group B: Control group.
BMI: Body Mass Index.
Duration of diabetes is presented as median (IQR).
IQR: 75th – 25th.
Sex is presented as a number (percent).
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score and Z-score at the baseline, to be sure if there is a
major difference between patients in groups.
3. Approximately 20 ml blood (after fasting for over
12 hours) was taken from every participant. Blood
samples were centrifuged within 3 hours of sampling
for 20 minute to obtain serum. Samples were frozen
at −80°C and they were immediately sent to the
hormone laboratory of Endocrinology and
Metabolism Research Institute (EMRI)/ Shariati
hospital/ TUMS. Baseline laboratory tests were
including a complete blood count, fasting blood
sugar, HbA1C, bone alkaline phosphatase,
osteocalcin, serum TNF-α, urine calcium and
creatinine, urine pyridinoline.
4. Monthly documentation of patient’s compliance to
therapy and acceptance of side effects.
5. Recording any probable side effects and necessary
managements.
The distribution of qualitative variables was assessed by
Kolmogorov-Smirnov test. Descriptive statistics, including
mean, median frequencies, and percentages, were used to
describe the population of study. Mean-Whitney U or TTable 2 Mean levels of bone markers before and after 3 mon
Variables Group A
Baseline 3rd month *P-value B
Pyridinoline 51.17 ± 87.90 13.06 ± 5.81 0.766 41.0
Osteocalcin 2.20 ± 0.47 2.5 ± 0.58 0.564 2.2
Urine Calcium 9.09 ± 9.08 8.10 ± 6.98 0.045 6.9
Urine Creatinine 120.55 ± 58.59 108.23 ± 48.99 0.273 111.
Bone Alkaline phosphatase 24.9 ± 7 20.8 ± 19.7 0.014 23
TNF-α 91.68 ± 52.92 88.84 ± 55.75 0.006 90.8
Group A: Diabetic patients on drug.
Group B: Control group.
*P-value according to paired T-test.
** P-value according to ANCOVA test.test and Chi-square test was performed for comparing
quantitative and qualitative variables between groups re-
spectively. The Analysis of covariance (ANCOVA) test was
used for comparison outcomes between case and control
group. Data were analyzed with SPSS software version 16
(SPSS Inc, Chicago, Illinois). P-values < 0.05 (2-sided test)
were considered statistically significant.
Results
Approximately eighty percent (78.7%) of participants
were women. The mean age of participants in interven-
tion and placebo group was respectively 51.87 ± 6.21 and
51.43 ± 5.37 years. The baseline characteristics of the
participants are shown in Table 1. There was no signifi-
cant difference in baseline characteristics and bone mar-
kers’ level between group A and B. After 3 months of
treatment, no statistically significant differences between
patients and controls were observed in pyridinoline,
osteocalcin, urine calcium, bone alkaline phosphatase
and TNF- α. Only urine creatinine level significantly
changed between two groups after 3 months of treat-
ment (p-value: 0.029). Table 2 shows mean levels of
bone markers before, after 3 months and difference
values between and within groups in intervention and
placebo groups.
Discussion
There are different hypothesis about the mechanisms of
diabetic bone disorders including oxidative stress [11].
Increasing number of osteoporotic patients in recent
years especially as a complication of diabetes mellitus
causes a need for an alternative new pharmacotherapy
which has better results and less complications compar-
ing to previous methods [2]. AngiparsW (Semelil) a new
herbal drug which is derived from a plant named Melilo-
tus Officinalis has been investigated as a useful new drug
in treatment of diabetic ulcers in a clinical trial study in
Iran [22].
Melilotus Officinalis has been proved to be helpful in
reducing inflammation, regulation of the immune systemth of treatment in drug (A) and placebo (B) groups
Group B Difference **P-
valueaseline 3rd month *P-value Group A Group B
1 ± 38.94 15.67 ± 11.05 0.268 −40.8 ± 96.5 −28.2 ± 42.6 0.656
2 ± 0.60 2.24 ± 0.82 0.230 0.37 ± 0.80 0.23 ± 0.96 0.390
5 ± 5.03 5.77 ± 6.31 0.044 −1 ± 9.1 0.21 ± 5.9 0.683
68 ± 72.39 130.39 ± 68.47 0.003 −11.2 ± 64 34.6 ± 49.2 0.029
.8 ± 10.4 20.6 ± 7.5 0.048 −4.5 ± 7 −3 ± 10.8 0.364
5 ± 27.21 80.94 ± 28.73 0.026 −4.2 ± 26.1 −12.4 ± 28.2 0.267
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thought to be due to the inhibitory effect of natural cou-
marin on oxidative DNA damage and formation [23,24].
No previously human or animal study has been pub-
lished on the effects of AngiparsW on bone markers in
diabetic patients. Although Leilei Bao et al. found that
some components in M. Officinalis were potent inhibi-
tors of osteoclastogenesis which leads to decrease in the
resorption capacity of osteoclasts [25], in this study no
significant changes were seen in bone markers due to
treatment with AngiparsW.
AngiparsW is a new herbal drug proved being useful in
healing diabetic foot ulcers however the exact mechan-
ism of its action is unknown yet. Our study showed that
this drug had no adverse effect or beneficial effect on
bone formation and bone resorption in diabetic patients.
Actually this study has some limitations including
small sample size and short length of the study. It seems
to us that a new study should be designed for another
6 months and a higher dose of AngiparsW to find out
whether it gives better results.
Conclusion
In conclusion, the findings of this study indicate that
AngiparsW had no beneficial or harmful effects on bone.
It might be other effects of this new component on bone
turnover process and markers which need more studies
and more time to be discovered.
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